Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Takeda
Pharma
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.
Angus Liu
May 17, 2024 8:30am
Takeda, Lilly-Innovent, BIO-China—Fierce Pharma Asia
May 10, 2024 9:30am
Takeda plots $900M restructuring plan as profits plummet
May 9, 2024 12:00pm
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
May 3, 2024 7:20am
Takeda joins growing list of drugmakers to leave trade group BIO
Apr 26, 2024 7:25am
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Apr 26, 2024 5:45am